CoChat

Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study.

Tawbi, Hussein Abdul-Hassan, Burgess, Melissa Amber, Crowley, John, Van Tine, Brian Andrew, Hu, James, Schuetze, Scott, D'Angelo, Sandra P., Attia, Steven, Priebat, Dennis A., Okuno, Scott H., Riedel, Richard F., Davis, Lara Emily, Movva, Sujana, Reed, Damon R., Baker, Laurence H., Reinke, Denise K., Maki, Robert G., Patel, Shreyaskumar, for SARC028 Investigators · 2016 · Journal of Clinical Oncology
Cited by 60

The DOI matches its Crossref record.

Abstract

11006 Background: Inhibition of the programmed death-1 (PD-1)-PD-ligand 1 (PD-L1) axis has shown durable clinical benefit in melanoma, lung, renal, and bladder carcinomas. Herein, we report results of the first phase II evaluation of PD-1 blockade with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced STS and BS. Methods: SARC028 is an open-label multicenter phase II study of single-agent P in pts with STS (Arm A) or BS (Arm B). All pts receive P 200mg IV q21 days. The primary endpoint for each arm is objective response rate (ORR) by RECIST 1.1 (target ORR = 25%, 82% power vs 10% ORR, α = 0.042). Secondary endpoints include safety, progression free survival (PFS), overall survival, and correlative studies. Tumor biopsies were collected at 0 and 8 weeks (mandatory), and at progression (optional). Arm A enrolled 4 subtypes in balanced cohorts: leiomyosarcoma (LMS), liposarcoma (LPS), undifferentiated pleomorphic sarcoma (UPS) and synovial sarcoma (SS). Arm B enrolled osteosarcoma (OS), Ewing sarcoma (ES) and high-grade/dedifferentiated chondrosarcoma (CS). Results: Of 80 patients enrolled at 12 SARC centers, 76 were evaluable for response by RECIST. In the STS cohort (Arm A), no objective responses were observed for LMS (0/10), LPS (0/9) or SS (0/10) from imaging performed after 8 weeks of therapy. An ORR of 22% was observed, however, for UPS (2/9). In the BS cohort (Arm B), 1 partial response (PR) was seen at 8 weeks in OS (1/19). No objective responses were observed in ES (0/13) or CS (0/6). In 24 pts that have completed evaluations at 20 weeks, 3 additional pts went on to experience PRs including 1 CS, 1 LPS and 1 UPS. PFS rate at 8 weeks was 50% in LMS, 63% in LPS, 30% in SS, 67% in UPS, 24% in OS, 9% in ES and 67% in CS. P was well tolerated and toxicities were consistent with published data. Conclusions: Single agent P has limited activity in unselected sarcoma pts. Early responses are infrequent but noted in UPS, OS, LPS and CS, warranting further investigation. Longer clinical follow-up data are critical to evaluate the therapeutic impact of single agent P in STS and BS and will be presented along with immune monitoring in peripheral blood and tumor tissues. Clinical trial information: NCT02301039.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.11006

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 60

Metadata

Authors
Tawbi, H. A.-H., Burgess, M. A., Crowley, J., Van Tine, B. A., Hu, J., Schuetze, S., D'Angelo, S. P., Attia, S., Priebat, D. A., Okuno, S. H., Riedel, R. F., Davis, L. E., Movva, S., Reed, D. R., Baker, L. H., Reinke, D. K., Maki, R. G., Patel, S., & for SARC028 Investigators
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
11006-11006
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2503301846
Cited by
60
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.11006
The paper
Tawbi, H. A.-H., Burgess, M. A., Crowley, J., Van Tine, B. A., Hu, J., Schuetze, S., D'Angelo, S. P., Attia, S., Priebat, D. A., Okuno, S. H., Riedel, R. F., Davis, L. E., Movva, S., Reed, D. R., Baker, L. H., Reinke, D. K., Maki, R. G., Patel, S., & for SARC028 Investigators. (2016). Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.11006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.